Skip to content

Released Mar 25, 2024, after the close

10-K filed Mar 25, 2024, 85 days after period end · 0000950170-24-035949

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$113.72Mderived+1,217.4% vs Q4 2022+572.0% vs Q3 2023
Net Income$31.07MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$43,152,000N/M
Operating Cash Flowderived$14,072,000N/M
Margins · derived
Operating margin37.9%+608.2 pt vs Q4 2022
Net margin27.3%+428.1 pt vs Q4 2022

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020
Revenue$113.72M$8.63M$10.65M$8.28M
Net Income$31.07M-$34.59M-$38.13M-$59.54M
EPS Diluted———-$1.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR